source
- Summit Therapeutics and Akeso celebrate third China approval for ivonescimab as new data show waning survival benefitSummit Therapeutics and its partner Akeso received a third approval in China for ivonescimab, a PD-1/VEGF bispecific antibody, for first-line treatment of advanced squamous non-small cell lung canc…
- Akeso and Summit’s lung cancer candidate shows worsening tumor progression, while Europe halts Tavneos over trial concernsAkeso Therapeutics and Summit Therapeutics reported that their combined lung cancer therapy failed to improve outcomes, with data indicating a worsening in tumor progression compared to control. T…STAT · 2mo agoNegative readoutNegative